Epistemonikos: El más rápido y confiable buscador de evidencia en salud

Gautret et al

ID: 5e830b1a7aaac82b57d8a86b

7 Documentos

Document ID

Thread ID

Cerrar

7 Referencias ( articles) loading

Revertir Estudificar

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Autores » Gautret, Philippe , Lagier, Jean-Christophe , Parola, Philippe , Hoang, Van Thuan , Meddeb, Line , Mailhe, Morgane , Doudier, Barbara , Courjon, Johan , Giordanengo, Valérie , Vieira, Vera Esteves , Dupont, Tissot , Honoré, Stéphane , Colson, Philippe , Chabrière, Eric , Scola, Bernard La , Rolain, Jean-Marc , Brouqui, Philippe , Raoult, Didier

Revista » International Journal of Antimicrobial Agents

Año » 2020

Enlaces » Pubmed DOI PubMed Central

Cargando información sobre las referencias

BACKGROUND: Chloroquine and hydroxychloroquine have been found to be efficient on SARS-CoV-2, and reported to be efficient in Chinese COV-19 patients. We evaluate the role of hydroxychloroquine on respiratory viral loads. PATIENTS AND METHODS: French Confirmed COVID-19 patients were included in a single arm protocol from early March to March 16th, to receive 600mg of hydroxychloroquine daily and their viral load in nasopharyngeal swabs was tested daily in a hospital setting. Depending on their clinical presentation, azithromycin was added to the treatment. Untreated patients from another center and cases refusing the protocol were included as negative controls. Presence and absence of virus at Day6-post inclusion was considered the end point. RESULTS: Six patients were asymptomatic, 22 had upper respiratory tract infection symptoms and eight had lower respiratory tract infection symptoms. Twenty cases were treated in this study and showed a significant reduction of the viral carriage at D6-post inclusion compared to controls, and much lower average carrying duration than reported of untreated patients in the literature. Azithromycin added to hydroxychloroquine was significantly more efficient for virus elimination. CONCLUSION: Despite its small sample size our survey shows that hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin.

Hydroxychloroquine and Azithromycin as a treatment of COVID-19: preliminary results of an open-label non-randomized clinical trial

Autores » Philippe GAUTRET , Jean Christophe LAGIER , Philippe PAROLA , Van Thuan HOANG , Line MEDDED , Morgan MAILHE , Barbara DOUDIER , Johan COURJON , Valerie GIORDANENGO , Vera ESTEVES VIEIRA , Herve TISSOT DUPONT , Stephane HONORE , Philippe COLSON , Eric CHABRIERE , Bernard LA SCOLA , Jean Marc ROLAIN , Philippe BROUQUI , Didier RAOULT Sr.

Pre-print » medRxiv

Año » 2020

Enlaces » DOI medRxiv

Cargando información sobre las referencias

BackgroundChloroquine and hydroxychloroquine have been found to be efficient on SARS-CoV-2, and reported to be efficient in Chinese COV-19 patients. We evaluate the role of hydroxychloroquine on respiratory viral loads. Patients and methodsPatients were included in a single arm protocol to receive 600mg of hydroxychloroquine daily and their viral load in nasal swabs was tested daily. Depending on their clinical presentation, azithromycin was added to the treatment. Untreated patients from another center and cases refusing the protocol were included as negative controls. Presence and absence of virus at Day6-post inclusion was considered the end point. ResultsTwenty cases were treated in this study and showed a significant reduction of the viral carriage at D6-post inclusion compared to controls, and much lower average carrying duration than reported of untreated patients in the literature. Azithromycin added to hydroxychloroquine was significantly more efficient for virus elimination. ConclusionHydroxychloroquine is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin.

Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study

Autores » Gautret P , Lagier JC , Parola P , Hoang VT , Meddebl , Sevestre J , Mailhe M , Doudier B , Aubry C , Amrane S , Seng P , Hocquart M , Finance J , Esteves Vieira V , Tissot Dupont H , Honoré S , Stein A , Million M , Colson P , La Scola B , Veit V , Jacquier A , Deharo JC , Drancourt M , Fournier PE , Rolain JM , Brouqui P , Raoult D

Revista » Travel Medicine and Infectious Disease

Año » 2020

Enlaces » DOI

Cargando información sobre las referencias

BACKGROUND: We need an effective treatment to cure COVID-19 patients and to decrease virus carriage duration. METHODS: We conducted an uncontrolled, non-comparative, observational study in a cohort of 80 relatively mildly infected inpatients treated with a combination of hydroxychloroquine and azithromycin over a period of at least three days, with three main measurements: clinical outcome, contagiousness as assessed by PCR and culture, and length of stay in infectious disease unit (IDU). RESULTS: All patients improved clinically except one 86 year-old patient who died, and one 74 year-old patient still in intensive care. A rapid fall of nasopharyngeal viral load was noted, with 83% negative at Day 7, and 93% at Day 8. Virus cultures from patient respiratory samples were negative in 97.5% of patients at Day 5. Consequently patients were able to be rapidly discharged from IDU with a mean length of stay of five days. CONCLUSION: We believe there is urgency to evaluate the effectiveness of this potentially-life saving therapeutic strategy at a larger scale, both to treat and cure patients at an early stage before irreversible severe respiratory complications take hold and to decrease duration of carriage and avoid the spread of the disease. Furthermore, the cost of treatment is negligible.

Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study.

Autores » Gautret P , Lagier JC , Parola P , Hoang VT , Meddeb L , Sevestre J , Mailhe M , Doudier B , Aubry C , Amrane S , Seng P , Hocquart M , Eldin C , Finance J , Vieira VE , Dupont HT , Honoré S , Stein A , Million M , Colson P , La Scola B , Veit V , Jacquier A , Deharo JC , Drancourt M , Fournier PE , Rolain JM , Brouqui P , Raoult D

Revista » Travel medicine and infectious disease

Año » 2020

Enlaces » Pubmed DOI PubMed Central

Cargando información sobre las referencias

BACKGROUND: We need an effective treatment to cure COVID-19 patients and to decrease virus carriage duration. METHODS: We conducted an uncontrolled non-comparative observational study in a cohort of 80 relatively mildly infected inpatients treated with a combination of hydroxychloroquine and azithromycin over a period of at least three days, with three main measurements: clinical outcome, contagiousness as assessed by PCR and culture, and length of stay in infectious disease unit (IDU). RESULTS: All patients improved clinically except one 86 year-old patient who died, and one 74 year-old patient still in intensive care. A rapid fall of nasopharyngeal viral load was noted, with 83% negative at Day7, and 93% at Day8. Virus cultures from patient respiratory samples were negative in 97.5% of patients at Day5. Consequently patients were able to be rapidly discharged from IDU with a mean length of stay of five days. CONCLUSION: We believe there is urgency to evaluate the effectiveness of this potentially-life saving therapeutic strategy at a larger scale, both to treat and cure patients at an early stage before irreversible severe respiratory complications take hold and to decrease duration of carriage and avoid the spread of the disease. Furthermore, the cost of treatment is negligible.

Response to effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.

Autores » Gautret P , Hoang VT , Lagier JC , Raoult D

Revista » International journal of antimicrobial agents

Año » 2021

Enlaces » Pubmed DOI PubMed Central

Cargando información sobre las referencias

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited.

Autores » Gautret P , Lagier JC , Honoré S , Hoang VT , Colson P , Raoult D

Revista » International journal of antimicrobial agents

Año » 2021

Enlaces » Pubmed DOI PubMed Central

Cargando información sobre las referencias

Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes.

Autores » Gautret P , Hoang VT , Lagier JC , Raoult D

Revista » International journal of antimicrobial agents

Año » 2021

Enlaces » Pubmed DOI PubMed Central

Cargando información sobre las referencias

BACKGROUND:

Chloroquine and hydroxychloroquine have been found to be efficient on SARS-CoV-2, and reported to be efficient in Chinese COV-19 patients. We evaluate the role of hydroxychloroquine on respiratory viral loads.

PATIENTS AND METHODS:

French Confirmed COVID-19 patients were included in a single arm protocol from early March to March 16th, to receive 600mg of hydroxychloroquine daily and their viral load in nasopharyngeal swabs was tested daily in a hospital setting. Depending on their clinical presentation, azithromycin was added to the treatment. Untreated patients from another center and cases refusing the protocol were included as negative controls. Presence and absence of virus at Day6-post inclusion was considered the end point.

RESULTS:

Six patients were asymptomatic, 22 had upper respiratory tract infection symptoms and eight had lower respiratory tract infection symptoms.
Twenty cases were treated in this study and showed a significant reduction of the viral carriage at D6-post inclusion compared to controls, and much lower average carrying duration than reported of untreated patients in the literature. Azithromycin added to hydroxychloroquine was significantly more efficient for virus elimination.

CONCLUSION:

Despite its small sample size our survey shows that hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin.